Evommune Announces Its Phase 2b Study Of EVO756 Oral Antagonist Failed To Meet Primary Endpoint Of Average Change In Participant's Urticaria Activity Score Over 7 Days At 12 Weeks

뉴스 본문을 불러오고 있어요.

Evommune Announces Its Phase 2b Study Of EVO756 Oral Antagonist Failed To Meet Primary Endpoint Of Average Change In Participant's Urticaria Activity Score Over 7 Days At 12 Weeks | 웨이프 WAPE

Evommune Announces Its Phase 2b Study Of EVO756 Oral Antagonist Failed To Meet Primary Endpoint Of Average Change In Participant's Urticaria Activity Score Over 7 Days At 12 Weeks

기사 요약

관련 종목

댓글 —